Capricor Therapeutics Inc (CAPR) fair value: what the stock is really worth
As of Oct 6, 2026: fair value of Capricor Therapeutics Inc $3.99, price $7.75, upside -48.6%, quality 23 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range $2.71 – $35.34 · fair‑value band $2.64 – $4.98 · the $7.75 price screens above the $3.99 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Capricor Therapeutics in your weekly email
Every Wednesday you see whether Capricor Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
Show more
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Stock analysis
Capricor Therapeutics Inc (CAPR) currently trades at $7.75, while our model-based Fair Value estimate is $3.99, 48.6% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $2.64 (bear) to $4.98 (bull), the price of $7.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Capricor Therapeutics Inc reported revenue of $0 in FY2025 versus $245K in FY2021. Reported net income was −$105M in FY2025.
Key figures
Market cap $551M · P/S ratio 49.5 · EPS (TTM) $−2.45 · Return on equity −73.7% · Return on assets (EBIT) −41.3% · Revenue (TTM) $11.1M · Revenue growth (YoY) −7.9% · Free cash flow −$72.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 78% below its 52-week high and 101% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −49%, CAPR screens richer than that median.
Fair Value models
Bear $2.64Fair Value $3.99Bull $4.98
Price $7.75 · Upside -48.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−11.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+349.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+85.8%
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+41.1%
’13
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−769.5% (2019) → −191.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Capricor Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 607 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score23 · Bottom 25%
Fair Value upside−48.6% · Below median
Profitability
Return on assets−33.6% · Bottom 25%
Operating margin (TTM)0.0% · Above median
Growth and dividend
Revenue growth−7.9% · Below median
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.80× · Pricier than median
P/S (TTM)49.47× · Priciest 25%
PEG0.38× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)99· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Capricor Therapeutics Inc (CAPR) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of $3.99 versus a price of $7.75, about −49% upside (overvalued).
What is the fair value of CAPR?
Our model-based fair value for Capricor Therapeutics Inc is $3.99 (as of Oct 2, 2026), built from audited fundamentals. The current price: $7.75.
What is the quality score of CAPR?
Capricor Therapeutics Inc has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Capricor Therapeutics Inc (CAPR)?
Our model-based price target is the fair value of $3.99 (as of Oct 2, 2026) from 1 valuation models. Cautious scenario $2.64, optimistic scenario $4.98. It is a calculation from audited fundamentals, not an analyst target.
What is the Capricor Therapeutics Inc stock forecast for 2026?
Our models put fair value at $3.99, about −49% upside versus a price of $7.75 (overvalued). Cautious scenario $2.64, optimistic scenario $4.98. The calculation is refreshed regularly with new filings.
What is the revenue of Capricor Therapeutics Inc (CAPR)?
Capricor Therapeutics Inc reported trailing-twelve-month revenue of about $11.1M (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of Capricor Therapeutics Inc (CAPR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Capricor Therapeutics Inc it is $3.99 per share (as of Oct 2, 2026), against a price of $7.75. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Capricor Therapeutics Inc stock overvalued or undervalued in 2026?
As of Oct 2, 2026, CAPR trades above its calculated fair value: price $7.75, fair value $3.99, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CAPR?
No. The price is what the market pays today ($7.75); the fair value is what the company's own numbers justify ($3.99). For Capricor Therapeutics Inc the two are $3.76 per share apart. That gap is exactly why we show both numbers side by side.
How much is Capricor Therapeutics Inc worth?
The market values Capricor Therapeutics Inc at about $551M (market capitalisation, as of Oct 2, 2026). Per share that is $7.75; our models calculate a fair value of $3.99 per share.
What do the bullish and bearish scenarios say about CAPR?
Our models span a range for Capricor Therapeutics Inc: cautious scenario $2.64, base $3.99, optimistic $4.98 per share (as of Oct 2, 2026, price $7.75). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of CAPR?
The PEG ratio of Capricor Therapeutics Inc is 0.38 (P/E divided by earnings growth, as of Oct 2, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Capricor Therapeutics Inc (CAPR)?
Balance-sheet figures for Capricor Therapeutics Inc (as of Oct 2, 2026): return on equity −73.7%, debt of 0.01 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is CAPR from its 52-week high?
Capricor Therapeutics Inc trades at $7.75, about 78% below its 52-week high of $35.34 and 101% above the low of $3.85 (as of Oct 6, 2026). Distance from the high says nothing about value: that is what the fair value of $3.99 is for.
Which stocks are comparable to Capricor Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Capricor Therapeutics Inc stock attractive at the current price?
The data as of Oct 2, 2026: price $7.75, calculated fair value $3.99 (−49%), Quality Score 23/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CAPR calculated?
We run Capricor Therapeutics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.99, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.4 % above its aggregate fair value. Capricor Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Capricor Therapeutics Inc (CAPR)?
The closing price on Oct 6, 2026 was $7.75. Our model-based fair value is $3.99, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Capricor Therapeutics Inc right now?
The price sits above even our optimistic bull case ($4.98). The favourable scenario is already priced in. Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.64 to $4.98) leaves room in how you read the outcome.
Key figures of Capricor Therapeutics Inc
How large is the market capitalisation of Capricor Therapeutics Inc (CAPR)?
The market capitalisation of Capricor Therapeutics Inc is $551M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Capricor Therapeutics Inc (CAPR)?
The price-to-sales ratio of Capricor Therapeutics Inc is 49.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Capricor Therapeutics Inc (CAPR)?
Earnings per share at Capricor Therapeutics Inc are $−2.45. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Capricor Therapeutics Inc (CAPR)?
The return on equity (ROE) of Capricor Therapeutics Inc is −73.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Capricor Therapeutics Inc (CAPR)?
On an EBIT basis the return on assets of Capricor Therapeutics Inc is −41.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Capricor Therapeutics Inc (CAPR)?
Revenue at Capricor Therapeutics Inc is growing −7.9% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Capricor Therapeutics Inc (CAPR) generate?
The free cash flow of Capricor Therapeutics Inc is −$72.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Capricor Therapeutics Inc (CAPR) hold?
Capricor Therapeutics Inc holds more cash than debt, $267M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Capricor Therapeutics Inc in the live analysis
One click puts Capricor Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Oct 2, 2026